FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Solid Biosciences Skyrockets as FDA lifts Hold on Trial”
Solid Biosciences (NASDAQ: SLDB) opened over 120% higher following the announcement that the FDA has lifted the clinical hold placed on the company’s IGNITE DMD Phase 1/2 clinical trial.
The trial for SGT-001 drug, which is a gene transfer therapy meant to focus on the underlying cause of Duchenne, a muscular dystrophy disorder, is set to restart by the first quarter of 2021.
Solid Biosciences is a life sciences company focused on advancing transformative treatments to improve the lives of patients living with Duchenne. Disease-focused and founded by a family directly impacted by Duchenne, our mandate is simple yet comprehensive – work to address the disease at its core by correcting the underlying mutation that causes Duchenne with our lead gene therapy candidate, SGT-001.
For more information, please visit: Solid Biosciences Inc.
About The Buzz: A Financial Buzz Show on daily news, covering the most up to date financial information. The Buzz intends to provide factual and relevant information for its audience. The Buzz is 100% original content, created by Financial Buzz Media. Located on Wall Street in the heart of New York City’s financial district, FinancialBuzz.com is a credible source for the world’s latest trending financial and economic news. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content.